FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010492803> ?p ?o ?g. }

• W2010492803 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCOxazaphosphorines are alkylating antineoplasic agents used in the treatment of cancer and have demonstrated activity against various tumor types, such as soft tissue sarcomas or lymphomas. Oxazaphosphorines are non-toxic prodrugs that require cytochrome P450 (CYP) bioactivation. In the case of Ifosfamide (IFO), the bioactivation produces the 4-OH-IFO, which after ring opening liberates the active nitrogen mustard displaying DNA cross-links. Associated toxicities of IFO are due to 1) acrolein, an urotoxic metabolite concomitantly generated with the nitrogen mustard and 2) chloroacetaldehyde, a neuro and nephrotoxic metabolite obtained by oxidation of the side chains (Kerbusch et al., 2001).To circumvent these toxicities, we have designed pre-activated oxazaphosphorines through electrochemical oxidation and binding of various moieties such as O-alkyl groups and S-alkyl groups. IFO is activated by oxidation of position 4 with labile moieties leading to pre-activated cytotoxic entities. We observed physical-chemical characteristics leading to nano-assemblies depending on the length of the linked moieties, which could bring tissue specificity for drug delivery purposes. Some of these pre-activated prodrugs may be constitutive of drug delivery systems, such as nanoparticules, aiming to address alkylating moieties to their target.We present here the use of different length moieties, from C1 (methoxy) to C30 (Squalenoyl, SQ) with intermediate length of C5 (Pentoxy) and C10 (Geranioxy and DimethylOctanoxy). These compounds are pre-activated formulation of IFO with C4-oxidation allowing to by-pass the CYP activation with direct release of 4-OH-IFO and then the alkylating mustard. Some of them, SQ-(O)-IFO, SQ-(S)-IFO and Geranioxy-IFO are able to self-assembly leading to nanoparticules. The length and nature of the engrafted moieties allow the study of the parameters that lead the kinetics of liberation of the activated compound.The nanoparticules have been fully characterized with a mean diameter of 182 nm for SQ-(O)-IFO and SQ-(S)-IFO and 130 nm for Geranioxy-IFO. The cytotoxic activity of SQ-(O)-IFO and SQ-(S)-IFO has been studied in vitro on a panel of 15 human and murine cancer lines (RMS-1, RD, TC71, A673, SK-N-MC, UW 479, Lan-5, SAOS-2, IGR-OV1, MCF-7(MDR), A549, M109, KB 3.1, B16F10, MiaPaCa-2). The cytotoxic activity of Pentoxy-IFO, Geranioxy-IFO and DimethylOctanoxy-IFO has been studied in vitro on a panel of 2 human cancer lines (A673 and RMS-1). All IFO derivatives present high in vitro activity while IFO has no activity on these cells. This proves the pre-activated property of these new compounds and the lack of CYP activation requirements. Their therapeutic activity is currently studied in vivo on human Ewing sarcoma TC71 and human Lung cancer A549 xenografts in mice after i.v. administration. These compounds are now patented.Citation Format: Charles Skarbek, Hubert Chapuis, Lea Lesueur, Michael Rivard, Thierry Martens, Didier Desmaele, Estelle Daudigeos-Dubus, Jean-Remi Bertrand, Alain Deroussent, Gilles Vassal, Patrick Couvreur, Angelo Paci. Enhanced activity of pre-activated oxazaphosphorine prodrugs designed for drug delivery strategy: influence of the length of the engrafted group. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5671. doi:10.1158/1538-7445.AM2013-5671" @default.
• W2010492803 created "2016-06-24" @default.
• W2010492803 creator A5013203026 @default.
• W2010492803 creator A5013335730 @default.
• W2010492803 creator A5015763391 @default.
• W2010492803 creator A5025015052 @default.
• W2010492803 creator A5036401831 @default.
• W2010492803 creator A5044894101 @default.
• W2010492803 creator A5048957528 @default.
• W2010492803 creator A5050630524 @default.
• W2010492803 creator A5056656682 @default.
• W2010492803 creator A5057238270 @default.
• W2010492803 creator A5067202962 @default.
• W2010492803 creator A5078174247 @default.
• W2010492803 date "2013-04-15" @default.
• W2010492803 modified "2023-09-26" @default.
• W2010492803 title "Abstract 5671: Enhanced activity of pre-activated oxazaphosphorine prodrugs designed for drug delivery strategy: influence of the length of the engrafted group." @default.
• W2010492803 doi "https://doi.org/10.1158/1538-7445.am2013-5671" @default.
• W2010492803 hasPublicationYear "2013" @default.
• W2010492803 type Work @default.
• W2010492803 sameAs 2010492803 @default.
• W2010492803 citedByCount "0" @default.
• W2010492803 crossrefType "proceedings-article" @default.
• W2010492803 hasAuthorship W2010492803A5013203026 @default.
• W2010492803 hasAuthorship W2010492803A5013335730 @default.
• W2010492803 hasAuthorship W2010492803A5015763391 @default.
• W2010492803 hasAuthorship W2010492803A5025015052 @default.
• W2010492803 hasAuthorship W2010492803A5036401831 @default.
• W2010492803 hasAuthorship W2010492803A5044894101 @default.
• W2010492803 hasAuthorship W2010492803A5048957528 @default.
• W2010492803 hasAuthorship W2010492803A5050630524 @default.
• W2010492803 hasAuthorship W2010492803A5056656682 @default.
• W2010492803 hasAuthorship W2010492803A5057238270 @default.
• W2010492803 hasAuthorship W2010492803A5067202962 @default.
• W2010492803 hasAuthorship W2010492803A5078174247 @default.
• W2010492803 hasConcept C108215921 @default.
• W2010492803 hasConcept C185592680 @default.
• W2010492803 hasConcept C21951064 @default.
• W2010492803 hasConcept C2776694085 @default.
• W2010492803 hasConcept C2776755627 @default.
• W2010492803 hasConcept C2777477808 @default.
• W2010492803 hasConcept C2777506904 @default.
• W2010492803 hasConcept C2778119113 @default.
• W2010492803 hasConcept C2778670039 @default.
• W2010492803 hasConcept C2780035454 @default.
• W2010492803 hasConcept C54355233 @default.
• W2010492803 hasConcept C55493867 @default.
• W2010492803 hasConcept C71240020 @default.
• W2010492803 hasConcept C86803240 @default.
• W2010492803 hasConcept C98274493 @default.
• W2010492803 hasConceptScore W2010492803C108215921 @default.
• W2010492803 hasConceptScore W2010492803C185592680 @default.
• W2010492803 hasConceptScore W2010492803C21951064 @default.
• W2010492803 hasConceptScore W2010492803C2776694085 @default.
• W2010492803 hasConceptScore W2010492803C2776755627 @default.
• W2010492803 hasConceptScore W2010492803C2777477808 @default.
• W2010492803 hasConceptScore W2010492803C2777506904 @default.
• W2010492803 hasConceptScore W2010492803C2778119113 @default.
• W2010492803 hasConceptScore W2010492803C2778670039 @default.
• W2010492803 hasConceptScore W2010492803C2780035454 @default.
• W2010492803 hasConceptScore W2010492803C54355233 @default.
• W2010492803 hasConceptScore W2010492803C55493867 @default.
• W2010492803 hasConceptScore W2010492803C71240020 @default.
• W2010492803 hasConceptScore W2010492803C86803240 @default.
• W2010492803 hasConceptScore W2010492803C98274493 @default.
• W2010492803 hasLocation W20104928031 @default.
• W2010492803 hasOpenAccess W2010492803 @default.
• W2010492803 hasPrimaryLocation W20104928031 @default.
• W2010492803 hasRelatedWork W1972675616 @default.
• W2010492803 hasRelatedWork W1991644508 @default.
• W2010492803 hasRelatedWork W1992394157 @default.
• W2010492803 hasRelatedWork W2000480642 @default.
• W2010492803 hasRelatedWork W2017370862 @default.
• W2010492803 hasRelatedWork W2022724334 @default.
• W2010492803 hasRelatedWork W2029326803 @default.
• W2010492803 hasRelatedWork W2034492448 @default.
• W2010492803 hasRelatedWork W2036473077 @default.
• W2010492803 hasRelatedWork W2038268619 @default.
• W2010492803 hasRelatedWork W2038509985 @default.
• W2010492803 hasRelatedWork W2058680960 @default.
• W2010492803 hasRelatedWork W2081266098 @default.
• W2010492803 hasRelatedWork W2084644380 @default.
• W2010492803 hasRelatedWork W2107748352 @default.
• W2010492803 hasRelatedWork W2566644413 @default.
• W2010492803 hasRelatedWork W2891276185 @default.
• W2010492803 hasRelatedWork W2903325038 @default.
• W2010492803 hasRelatedWork W2949530624 @default.
• W2010492803 hasRelatedWork W2951535078 @default.
• W2010492803 isParatext "false" @default.
• W2010492803 isRetracted "false" @default.
• W2010492803 magId "2010492803" @default.
• W2010492803 workType "article" @default.